Do You Lose Belly Fat on Semaglutide? What the Evidence Shows About Visceral Fat (2026)

Yes — you do lose belly fat on semaglutide. Semaglutide (the active ingredient in Ozempic and Wegovy) drives loss of total body fat, and importantly it reduces visceral fat: the metabolically harmful fat packed around your abdominal organs that drives cardiometabolic risk. In a body-composition substudy of the SUSTAIN 8 trial that used DXA imaging, once-weekly semaglutide reduced total fat mass and visceral adipose tissue, and the proportion of fat in body mass fell while lean mass made up a larger share of what remained.^[1] The pivotal STEP-1 obesity trial showed semaglutide 2.4 mg cut mean body weight by about 15% and waist circumference by roughly 13 cm versus placebo over 68 weeks — a direct, measurable shrinking of the midsection.^[2] The honest nuances matter too: you cannot spot-reduce belly fat, some lean (muscle) mass comes off alongside the fat, and visceral-fat loss is a big part of why semaglutide improves blood pressure, lipids, and glucose. This is general information, not medical advice — your prescriber individualizes your care. See our Ozempic and Wegovy drug pages for the full profiles.

Does semaglutide actually reduce belly fat?

Yes. The most rigorous evidence comes from body-composition substudies that image fat directly. In the SUSTAIN 8 body-composition substudy, adults with type 2 diabetes who took once-weekly semaglutide underwent DXA scanning that separated total fat mass, lean body mass, and visceral adipose tissue (VAT — the deep fat around the abdominal organs). Semaglutide reduced both total fat mass and visceral adipose tissue, and the percentage of total fat in the body fell while lean tissue made up a larger share of the lighter body that remained.^[1] That is the key point: the weight you lose on semaglutide is predominantly fat, and the belly is one of the places that fat comes off.

The obesity trials reinforce this with a simpler, clinic-friendly measure: waist circumference. In STEP-1, semaglutide 2.4 mg once-weekly reduced mean body weight by about 14.9% versus 2.4% on placebo, and it reduced waist circumference by approximately 13.5 cm versus about 4.1 cm on placebo over 68 weeks.^[2] A shrinking waistline is the most accessible real-world signal that abdominal fat — including the harmful visceral component — is coming down, which is why prescribers often track the tape measure alongside the scale.

Why you lose belly fat — and why you can't target it

Semaglutide does not have a "belly-fat" mechanism. It is a GLP-1 receptor agonist that reduces appetite and energy intake, which puts the body into an energy deficit. In that deficit the body draws on fat stores throughout the body — you lose belly fat because you are losing fat everywhere. There is no drug, food, exercise, or supplement that selectively removes fat from one region: spot-reduction is a myth, and semaglutide is no exception.

The encouraging wrinkle is that visceral fat tends to be mobilized readily and relatively early in weight loss. Visceral adipose tissue is metabolically active and lipolytically responsive, so it often comes off in good proportion as total fat mass falls — which is exactly the pattern the DXA substudy captured when it showed reductions in both total fat and the visceral compartment.^[1] So while you cannot aim the fat loss at your abdomen, the abdomen is frequently one of the first beneficiaries.

The honest caveat: you lose some muscle too

Any meaningful weight loss — from semaglutide, surgery, or diet alone — removes some lean (muscle) mass along with the fat. Across weight-loss interventions, lean tissue commonly accounts for roughly a quarter to two-fifths of the total weight lost, with the exact split depending on the deficit, protein intake, baseline body composition, and how much resistance training is in the picture. The DXA substudy is reassuring on the direction — semaglutide lowered the percentage of fat and left lean tissue as a larger share of the body — but it does not mean zero muscle is lost.^[1] Preserving lean mass is something you actively influence: adequate protein and resistance (strength) training are the two levers that shift the fat-to-lean ratio of your weight loss in your favor. We cover this in depth in our semaglutide and muscle / lean-mass loss guide.

How to read this chart. The figures are illustrative of the direction and rough proportions seen in body-composition substudies — most of the weight lost on semaglutide is fat, a meaningful slice of that fat is visceral, and a smaller fraction is lean mass. They are not a measured outcome from any single patient or a guaranteed split. The "fat" and "visceral" bars overlap (visceral fat is part of total fat mass), so they are not meant to sum to 100%. Your own ratio depends heavily on protein intake and whether you strength-train.

Why visceral-fat loss is the cardiometabolic prize

Losing belly fat on semaglutide is not just cosmetic. Visceral adipose tissue is the metabolically dangerous fat — it sits around the liver, pancreas, and intestines, releases inflammatory signals and free fatty acids into the portal circulation, and is tightly linked to insulin resistance, high blood pressure, abnormal lipids, and fatty liver disease (MASLD, formerly NAFLD). Reducing the visceral compartment is a major reason semaglutide improves these markers, and the SUSTAIN 8 substudy's finding that semaglutide lowers VAT is mechanistically consistent with the blood-sugar, blood-pressure, and lipid improvements seen across the semaglutide trial program.^[1][2] In other words, the shrinking waistline is a visible proxy for an invisible, clinically important shift in where your fat used to be.

One cosmetic flip side is worth naming honestly: because the fat loss is generalized, some people also lose subcutaneous facial fat — the "Ozempic face" effect. It is not a separate side effect so much as the same whole-body fat loss showing up in the cheeks and temples; it tends to be more noticeable with faster or larger weight loss. See Ozempic side effects for the broader picture.

How long until you lose belly fat — and how to measure it

Belly-fat loss on semaglutide is a weeks-to-months process, not days. Semaglutide is titrated upward in steps, and the appetite reduction — and the fat loss that follows — builds as the dose climbs and as the energy deficit accumulates. The STEP-1 and SUSTAIN 8 results reflect months of treatment (68 weeks and through end of trial, respectively), so set expectations on that horizon rather than expecting a flat stomach in a few weeks.^[1][2] Practical guidance:

• Measure your waist, not just the scale. A tape measure at the navel captures abdominal-fat change that body weight alone can miss — especially if you are preserving or building muscle while losing fat. STEP-1 tracked waist circumference for exactly this reason.^[2]
• Prioritize protein. Adequate daily protein is the single biggest dietary lever for keeping lean mass while you lose fat, which improves the fat-to-lean ratio of your weight loss.
• Add resistance training. Strength training signals the body to retain muscle during an energy deficit, helping ensure more of the weight you lose is fat — including visceral fat. See our muscle-loss guide for specifics.
• Stay hydrated and don't crash-diet. Aggressive under-eating on top of semaglutide's appetite suppression increases lean-mass loss and side effects without speeding fat loss in a healthy way.
• Be patient through titration. The largest body-composition changes in the trials accrued over many months at the higher maintenance doses, not in the first few low-dose weeks.^[2]

Ready to start? Top vetted semaglutide providers

If you and a licensed prescriber decide semaglutide is appropriate for you, these are the vetted telehealth providers in our directory that offer compounded semaglutide, ranked by our editorial score. No insurance is required, and our editors verify each listing. For the lowest-cost legitimate options across every channel, see our cheapest GLP-1 without insurance buyer's guide.

Bottom line

• Yes — you lose belly fat on semaglutide. It drives loss of total body fat and reduces visceral (belly) fat, the metabolically harmful fat around the abdominal organs, per a DXA body-composition substudy of SUSTAIN 8.^[1]
• In STEP-1, semaglutide 2.4 mg cut mean body weight by about 15% and waist circumference by roughly 13 cm versus placebo over 68 weeks — a measurable shrinking of the midsection.^[2]
• You cannot spot-reduce. You lose belly fat because you lose fat throughout the body; visceral fat just tends to be mobilized readily and relatively early.
• Some lean (muscle) mass comes off too. Protect it with adequate protein and resistance training to improve the fat-to-lean ratio of your weight loss — see our muscle-loss guide.
• Visceral-fat loss is a major reason semaglutide improves blood pressure, lipids, glucose, and liver fat — the shrinking waist is a proxy for a real cardiometabolic shift.
• Belly-fat loss takes weeks to months; measure your waist, not just the scale, and be patient through dose titration.
• This is general information, not medical advice. Talk to a licensed prescriber. For access options see our best semaglutide providers and the cheapest GLP-1 without insurance guide.

Frequently asked questions

Related research

• Semaglutide and muscle / lean-mass loss — how much muscle you lose with the fat, and the protein-and-resistance-training playbook to protect it.
• Ozempic (semaglutide) side effects — the full adverse-effect profile, including the cosmetic facial-fat ("Ozempic face") effect of generalized fat loss.
• Cheapest GLP-1 without insurance — every legitimate cash-pay channel for semaglutide and other GLP-1s, ranked cheapest first.
• Best semaglutide providers — our ranked, editor-vetted directory of telehealth providers offering semaglutide.
• Ozempic drug page and Wegovy drug page — the full semaglutide profiles, dosing, and labeling.

Citation verification. PMIDs 31897524 (McCrimmon et al., SUSTAIN 8 body-composition substudy, Diabetologia 2020) and 33567185 (Wilding et al., STEP-1, N Engl J Med 2021) were verified live via the PubMed E-utilities esummary API for matching title and first-author byline. The body-composition and visceral-fat reductions are described qualitatively where the source reports them as such; the STEP-1 waist-circumference and weight-loss figures are taken from the published primary report. The body-composition chart in this article is explicitly illustrative of the typical direction and rough proportions seen in DXA substudies, not a measured per-patient outcome.

Important disclaimer. This article is general educational information only — not medical advice and not a substitute for consultation with a licensed prescriber. Weight loss and GLP-1 therapy are YMYL (Your Money or Your Life) topics. Individual body-composition results vary widely with dose, diet, protein intake, resistance training, and baseline body composition; the trial figures cited are study-level averages, not personal predictions. Do not start, stop, or change semaglutide or any other medication on your own. Talk to your prescriber about whether semaglutide is appropriate for you.